Prolonged survival of a patient with active MDR-TB HIV co-morbidity: Insights from a Mycobacterium tuberculosis strain with a unique genomic deletion

Author:

Rubinstein Mor,Makhon Andrei,Losev Yelena,Valenci Gal Zizelski,Gatt Yair E.,Margalit Hanah,Fass Ephraim,Kutikov Ina,Murik Omer,Zeevi David A.,Savyon Michal,Tau Luba,Shwartz Hasia Kaidar,Dveyrin Zeev,Rorman Efrat,Nissan IsraelORCID

Abstract

AbstractCoinfection of HIV and multidrug-resistant tuberculosis (MDR-TB) presents significant challenges in terms of the treatment and prognosis of tuberculosis, leading to complexities in managing the disease and impacting the overall outcome for TB patients. This study presents a remarkable case of a patient with MDR-TB and HIV coinfection who survived for over eight years, despite poor treatment adherence and comorbidities. Whole genome sequencing (WGS) of the infectingMycobacterium tuberculosis(Mtb) strain revealed a unique genomic deletion, spanning 18 genes, including key genes involved in hypoxia response, intracellular survival, immunodominant antigens and dormancy. This deletion, that we have called “Del-X”, potentially exerts a profound influence on the bacterial physiology and its virulence. Only few similar deletions were detected in other non-relatedMtbgenomes worldwide.In vivoevolution analysis identified drug resistance and metabolic adaptation mutations and their temporal dynamics during the patient’s treatment course.

Publisher

Cold Spring Harbor Laboratory

Reference85 articles.

1. Organization, World Health. Global tuberculosis report 2022. Geneva : World Health Organization ; 2022. Licence: CC BY-NC-SA 3.0 IGO. 2022: Geneva

2. WHO operational handbook on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

3. Tuberculosis—a World Health Organization Perspective

4. World Health Organization treatment outcome definitions for tuberculosis: 2021 update

5. Evolution of Drug Resistance in Mycobacterium tuberculosis : Clinical and Molecular Perspective

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3